Mometasone furoate nasal spray reduces the ocular symptoms of seasonal allergic rhinitis
- PMID: 20434199
- DOI: 10.1016/j.jaci.2010.03.004
Mometasone furoate nasal spray reduces the ocular symptoms of seasonal allergic rhinitis
Abstract
Background: Mometasone furoate nasal spray (MFNS), a potent intranasal corticosteroid with proved efficacy in relieving nasal allergic rhinitis symptoms, has demonstrated effectiveness in improving ocular symptoms associated with seasonal allergic rhinitis (SAR) in retrospective analyses.
Objective: We sought to evaluate prospectively the efficacy of MFNS in reducing total ocular symptom scores (TOSSs) and individual ocular symptoms in subjects with SAR.
Methods: Subjects 12 years or older (n = 429) with moderate-to-severe baseline symptoms were randomized to MFNS, 200 microg once daily, or placebo in this 15-day, double-blind, parallel-group study. Subjects evaluated morning instantaneous TOSSs and daily reflective TOSSs, total nasal symptom scores (TNSSs; both instantaneous TNSSs and reflective TNSSs, respectively), and individual ocular and nasal symptoms. Mean changes from baseline averaged over days 2 to 15 (instantaneous) and days 1 to 15 (reflective) were calculated. Quality of life was assessed by using the Rhinoconjunctivitis Quality of Life Questionnaire.
Results: MFNS treatment yielded significant reductions from baseline versus placebo in instantaneous TOSSs (-0.34, P = .026, coprimary end point), instantaneous TNSSs (-0.88, P < .001, coprimary end point), reflective TOSSs (-0.44, P = .005), and reflective TNSSs (-1.06, P < .001). Significant decreases in all individual reflective ocular symptoms and instantaneous eye itching/burning and eye watering/tearing were observed for MFNS versus placebo (P < .05). Numeric improvements in instantaneous eye redness were seen but did not reach statistical significance. Improvements in Rhinoconjunctivitis Quality of Life Questionnaire total scores and individual symptom domains were achieved with MFNS treatment versus placebo (P < .001). MFNS was well tolerated.
Conclusion: This prospective study demonstrates that MFNS significantly reduces ocular symptoms in subjects with SAR.
Copyright (c) 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
Comment in
-
Fluticasone furoate nasal spray is the only intranasal corticosteroid to reduce the ocular symptoms of seasonal allergic rhinitis consistently.J Allergy Clin Immunol. 2011 Jan;127(1):288-9; author reply 289. doi: 10.1016/j.jaci.2010.08.046. Epub 2010 Nov 3. J Allergy Clin Immunol. 2011. PMID: 21047674 No abstract available.
Similar articles
-
Relief of cough and nasal symptoms associated with allergic rhinitis by mometasone furoate nasal spray.Ann Allergy Asthma Immunol. 2003 Apr;90(4):416-21. doi: 10.1016/S1081-1206(10)61826-1. Ann Allergy Asthma Immunol. 2003. PMID: 12722964 Clinical Trial.
-
Effects of intranasal mometasone furoate on itchy ear and palate in patients with seasonal allergic rhinitis.Ann Allergy Asthma Immunol. 2012 May;108(5):359-62. doi: 10.1016/j.anai.2012.02.023. Epub 2012 Mar 23. Ann Allergy Asthma Immunol. 2012. PMID: 22541408 Clinical Trial.
-
Intranasal mometasone furoate alleviates the ocular symptoms associated with seasonal allergic rhinitis: results of a post hoc analysis.Int Arch Allergy Immunol. 2008;147(4):323-30. doi: 10.1159/000144040. Epub 2008 Jul 12. Int Arch Allergy Immunol. 2008. PMID: 18622139 Clinical Trial.
-
Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis. Meta-analysis of randomized, double-blind, placebo-controlled, clinical trials.Allergy. 2008 Oct;63(10):1280-91. doi: 10.1111/j.1398-9995.2008.01808.x. Epub 2008 Aug 21. Allergy. 2008. PMID: 18721246 Review.
-
Nasal allergies and beyond: a clinical review of the pharmacology, efficacy, and safety of mometasone furoate.Allergy. 2005;60 Suppl 80:5-19. doi: 10.1111/j.1398-9995.2005.00917.x. Allergy. 2005. PMID: 15948774 Review.
Cited by
-
Comparative efficacy and acceptability of licensed dose intranasal corticosteroids for moderate-to-severe allergic rhinitis: a systematic review and network meta-analysis.Front Pharmacol. 2023 May 23;14:1184552. doi: 10.3389/fphar.2023.1184552. eCollection 2023. Front Pharmacol. 2023. PMID: 37288109 Free PMC article. Review.
-
A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis.BMC Med. 2014 May 1;12:71. doi: 10.1186/1741-7015-12-71. BMC Med. 2014. PMID: 24885894 Free PMC article. Review.
-
Intranasal steroids in the treatment of allergy-induced rhinorrhea.Clin Rev Allergy Immunol. 2011 Aug;41(1):89-101. doi: 10.1007/s12016-010-8206-2. Clin Rev Allergy Immunol. 2011. PMID: 20514529 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
